{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-213491","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.990523+00:00","generated_at":"2026-05-14T21:09:53.160328+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tango Therapeutics CFO Daniella Beckman Separates; Severance Includes 12-Month Pay, Equity Acceleration","bullets":["CFO Daniella Beckman ceased serving as principal financial officer effective April 15, 2026.","Separation agreement provides 12 months severance at current base salary paid over 12 months.","Company accelerates vesting of equity awards that would have vested in 24 months following May 1, 2026.","Vested stock options exercise period extended through August 31, 2026.","Beckman executed a general release in favor of the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213491","json":"https://secwatch.observer/filing/0001193125-26-213491.json","markdown":"https://secwatch.observer/filing/0001193125-26-213491.md","text":"https://secwatch.observer/filing/0001193125-26-213491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526213491/0001193125-26-213491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526213491/d102174d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-14T21:09:53.160328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a44c41735e","claim":"Daniella Beckman departed as Chief Financial Officer at Tango Therapeutics, Inc..","evidence_excerpt":"on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526213491/0001193125-26-213491-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}